Pharma Bavaria Int. further extends its partnership for Combofusiv™ (AFT’s innovative Paracetamol/Ibuprofen IV formulation) to Sub-Saharan African markets.

After Central America, the Caribbean and Latin America, Pharma Bavaria International is expanding the territory of its brand Combofusiv™ (AFT’s brand: Maxigesic® IV) to additional 38 markets in Sub-Saharan Africa by signing an extension to the license agreement with AFT Pharmaceuticals (NZ).

Combofusiv™/ (Paracetamol 1000mg + Ibuprofen 300mg solution for infusion) has been developed by AFT as patented, intravenous formulation, for use in post-operative pain management; also sparing opioids. Combofusiv™ provides significantly better pain relief than either Paracetamol IV or Ibuprofen IV alone in the same doses.

“Pharma Bavaria Int. has grown a strong position in pain management in several African markets during the past years. The introduction of Combofusiv™ comprises the next step in adding an innovative treatment option to some of our key markets. “Combofusiv™ is definitely a great add-on to one of our strongest brands: Parafusiv™ (Paracetamol IV)”, Pharma Bavaria’s Chief Executive Officer Dr. Manuel Heim says: “We are very excited to extend our excellent collaboration with AFT to Africa, which is underlining our proven competence in the therapeutic area in these territories. With our strong presence in East and West Africa we are looking forward to a fast and successful market access.”

Gagan Datta, Pharma Bavaria’s Chief Commercial Officer added: “I am very delighted to introduce Combofusiv™ to our markets in Africa. This innovative formulation will give healthcare professionals a great new treatment option for successful pain management and will be of great value for the patients.”

About Pharma Bavaria International
Pharma Bavaria International Group distributes and promotes high-quality pharmaceuticals with well-researched ingredients in more than 45 countries under its own brand. With a strong focus on growth regions such as the Middle East, Africa, South-East Asia and LATAM and other emerging economies Pharma Bavaria’s portfolio of prescription medicines includes anti-infectives, analgesic/anti-inflammatory, flu and cold, gastroenterology, oncology, cardiology, and women’s healthcare areas and is added up with a range of OTC products. For more information visit our website: or follow us on LinkedIn and/or YouTube

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. AFT’s product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. AFT’s  business model is to develop and in-license products for sale by their own dedicated sales teams in Australia, New Zealand and in certain Southeast Asian markets, and to out-license their products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit: